The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Science from our Sisters

Science from our Sisters

August 1, 2008 • By From the College

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Rituximab Can Improve Quality of Life in RA

Rituximab may be a good option for treating patients with active rheumatoid arthritis (RA) that does not respond to anti–tumor necrosis factor (TNF) therapy, according to a study published in Arthritis Care & Research (2008;59:785-793).

You Might Also Like
  • Science from our Sisters
  • Science From Our Sisters
  • Science from our Sisters
Explore This Issue
August 2008
Also By This Author
  • Coding Corner Answer

In this study, patients with active RA received either rituximab (298 patients) or placebo (201 patients), in addition to methotrexate, folate, intravenous methylprednisolone before infusions, and oral prednisone. Patients received rituximab or placebo on days 1 and 15, and were followed for 24 weeks using the ACR 20% response, the Health Assessment Questionnaire disability index, the Functional Assessment of Chronic Illness Therapy–Fatigue, and the Short Form 36.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

By week 24, patients treated with rituximab had statistically significant improvements in pain, fatigue, functional disability, quality of life, and disease activity when compared with patients treated with placebo.

The study authors point out that this research adds to evidence that rituximab can be an effective treatment option for patients who have a poor response to therapy or who cannot take anti-TNF agents because of side effects. Rituximab, they write, “meaningfully improves patients’ perceptions of their disease.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Filed Under: Conditions, Research Reviews, Rheumatoid Arthritis Tagged With: A&R, AC&R, ResearchIssue: August 2008

You Might Also Like:
  • Science from our Sisters
  • Science From Our Sisters
  • Science from our Sisters
  • Science from our Sisters

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.